Isogenica is proud to announce two new Non-Executive Directors

Feb 19, 2024

Isogenica is pleased to welcome both Paul Clewlow and Trevor Phillips as our new Non-Executive Directors to the team.

Paul and Trevor will play a crucial role in providing independent oversight, constructive challenge, and strategic guidance to Isogenica.

Paul, with his considerable experience at the Board level within the CRO sector of the pharmaceutical industry and as a life sciences consultant, is well-equipped to offer strategic advice on building and running science-driven companies.

His expertise in devising strategies for growth and profitability, as well as his skill in managing and motivating people, will be an invaluable asset to Isogenica’s leadership team.

Similarly, Trevor’s background in Board and C-level leadership roles in pharma, biotech, and CROs in Europe and the US makes him an ideal candidate for the role of Non-Executive Director. His key strengths in strategy, planning, operations, business turnaround, product development, and commercialisation will provide Isogenica with valuable insights as the company continues to navigate the complex landscape of the biotechnology industry.

Overall, Paul and Trevor’s appointment as Non-Executive Directors underscores Isogenica’s commitment to excellence and innovation, and we look forward to benefiting from their expertise as we continue to pursue our strategic objectives and drive value for our shareholders.

Further Information

About Isogenica 

Isogenica is a biotechnology company specialising in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific biotherapeutics. Drawing on more than 20 years at the forefront of antibody discovery and engineering, we have built a unique and proven engine for biotherapeutic development and a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes. 

For further information, visit    


Business Development Team

T +44 1799 533 680